You need JavaScript to view this

Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy

Abstract

In order to assess value of serum prostate-specific antigen (PSA) levels in the monitoring of patients with localized prostatic carcinoma undergoing radical radiation therapy, 146 previously untreated patients were studied. To the prostate 60-70 Gy were administered over 8-9 weeks. Median follow-up was 28 every 3 months during 1st year and every 6 months after. Pre-treatment PSA values exceeded 10 ng/ml in 62%. Initial PSA values were correlated with tumor size and Gleason score. PSA levels decreased 6 months after completion of radiation therapy, compared to initial value in 88.3%. It had fallen to 10 ng/ml or less in 59% with initial abnormal PSA levels. Patients whose initial PSA exceeded 50 ng/ml attained levels of 10 ng/ml or less in only 19%. Only 3/55 with both initial and 6-month PSA values of about 10 ng/ml developed metastases. Of 91 patients with initial PSA values over 10 ng/ml 54 had a 6-month PSA level of 10 ng/ml or less, and only 4/54 relapsed. By contrast, 13/37 patients with a 6-month PSA level persistently above 10 ng/ml relapsed. The 3-year relapse-free survival is 85.1% for 6-month PSA level of about 10 ng/ml, and 50.2% for patients with persistently elevated PSA values. The  More>>
Authors:
Fijuth, J; Chauvet, B; Vincent, P; Felix-Faure, C; Reboul, F [1] 
  1. Clinique Saint-Catherine, Avignon (France)
Publication Date:
Apr 01, 1992
Product Type:
Journal Article
Reference Number:
AIX-24-019247; EDB-93-041512
Resource Relation:
Journal Name: Radiotherapy and Oncology; (Netherlands); Journal Volume: 23:4
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANTIGENS; BLOOD CHEMISTRY; CARCINOMAS; RADIOTHERAPY; PROSTATE; BIOASSAY; BIOLOGICAL RECOVERY; IMMUNE SERUMS; METASTASES; NUMERICAL DATA; PATIENTS; SURVIVAL CURVES; BIOCHEMISTRY; BODY; CHEMISTRY; DATA; DISEASES; GLANDS; INFORMATION; MALE GENITALS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; THERAPY; 550603* - Medicine- External Radiation in Therapy- (1980-)
OSTI ID:
6824107
Country of Origin:
Netherlands
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 0167-8140; CODEN: RAONDT
Submitting Site:
NLN
Size:
Pages: 236-240
Announcement Date:
Apr 01, 1993

Citation Formats

Fijuth, J, Chauvet, B, Vincent, P, Felix-Faure, C, and Reboul, F. Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy. Netherlands: N. p., 1992. Web. doi:10.1016/S0167-8140(92)80127-5.
Fijuth, J, Chauvet, B, Vincent, P, Felix-Faure, C, & Reboul, F. Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy. Netherlands. doi:10.1016/S0167-8140(92)80127-5.
Fijuth, J, Chauvet, B, Vincent, P, Felix-Faure, C, and Reboul, F. 1992. "Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy." Netherlands. doi:10.1016/S0167-8140(92)80127-5. https://www.osti.gov/servlets/purl/10.1016/S0167-8140(92)80127-5.
@misc{etde_6824107,
title = {Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy}
author = {Fijuth, J, Chauvet, B, Vincent, P, Felix-Faure, C, and Reboul, F}
abstractNote = {In order to assess value of serum prostate-specific antigen (PSA) levels in the monitoring of patients with localized prostatic carcinoma undergoing radical radiation therapy, 146 previously untreated patients were studied. To the prostate 60-70 Gy were administered over 8-9 weeks. Median follow-up was 28 every 3 months during 1st year and every 6 months after. Pre-treatment PSA values exceeded 10 ng/ml in 62%. Initial PSA values were correlated with tumor size and Gleason score. PSA levels decreased 6 months after completion of radiation therapy, compared to initial value in 88.3%. It had fallen to 10 ng/ml or less in 59% with initial abnormal PSA levels. Patients whose initial PSA exceeded 50 ng/ml attained levels of 10 ng/ml or less in only 19%. Only 3/55 with both initial and 6-month PSA values of about 10 ng/ml developed metastases. Of 91 patients with initial PSA values over 10 ng/ml 54 had a 6-month PSA level of 10 ng/ml or less, and only 4/54 relapsed. By contrast, 13/37 patients with a 6-month PSA level persistently above 10 ng/ml relapsed. The 3-year relapse-free survival is 85.1% for 6-month PSA level of about 10 ng/ml, and 50.2% for patients with persistently elevated PSA values. The pattern of decline of PSA level was also analyzed: 11/22 patients with initial PSA>10 ng/ml and relative difference between an initial and a 6-month PSA value of less than 50%, developed metastases. By contrast, when relative difference was greater than 50%, only 6/69 belonging to this group had local recurrence or developed metastases. The 3-year relapse-free survival rate was significantly superior in latter group.}
doi = {10.1016/S0167-8140(92)80127-5}
journal = {Radiotherapy and Oncology; (Netherlands)}
volume = {23:4}
journal type = {AC}
place = {Netherlands}
year = {1992}
month = {Apr}
}